DK1569679T3 - Chaperonin-10-immunosuppression - Google Patents

Chaperonin-10-immunosuppression

Info

Publication number
DK1569679T3
DK1569679T3 DK03769073.2T DK03769073T DK1569679T3 DK 1569679 T3 DK1569679 T3 DK 1569679T3 DK 03769073 T DK03769073 T DK 03769073T DK 1569679 T3 DK1569679 T3 DK 1569679T3
Authority
DK
Denmark
Prior art keywords
donor
recipient animal
cpn10
administration
host disease
Prior art date
Application number
DK03769073.2T
Other languages
English (en)
Inventor
Halle Morton
Alice Christina Cavanagh
Tatjana Banovic
Geoffrey R Hill
Original Assignee
Cbio Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cbio Ltd filed Critical Cbio Ltd
Application granted granted Critical
Publication of DK1569679T3 publication Critical patent/DK1569679T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Glass Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK03769073.2T 2002-11-06 2003-11-06 Chaperonin-10-immunosuppression DK1569679T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2002952492A AU2002952492A0 (en) 2002-11-06 2002-11-06 Chaperonin 10 immunosuppression
PCT/AU2003/001467 WO2004041300A1 (en) 2002-11-06 2003-11-06 Chaperonin 10 immunosuppression

Publications (1)

Publication Number Publication Date
DK1569679T3 true DK1569679T3 (da) 2011-01-10

Family

ID=28795882

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03769073.2T DK1569679T3 (da) 2002-11-06 2003-11-06 Chaperonin-10-immunosuppression

Country Status (16)

Country Link
US (3) US7618935B2 (da)
EP (3) EP2818179A1 (da)
JP (2) JP4716731B2 (da)
KR (1) KR101088740B1 (da)
CN (1) CN100525832C (da)
AT (1) ATE489963T1 (da)
AU (1) AU2002952492A0 (da)
CA (1) CA2505141C (da)
CY (1) CY1110972T1 (da)
DE (1) DE60335202D1 (da)
DK (1) DK1569679T3 (da)
ES (1) ES2351993T3 (da)
NZ (1) NZ540433A (da)
PT (1) PT1569679E (da)
SI (1) SI1569679T1 (da)
WO (1) WO2004041300A1 (da)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005204979B2 (en) * 2004-01-16 2010-10-21 Cbio Limited Chaperonin 10 modulation of toll-like receptor-inducible cytokine and chemokine secretion
KR20060114011A (ko) 2004-01-16 2006-11-03 씨바이오 리미티드 Ｔｏｌｌ-유사 수용체 유도성 사이토킨 및 케모킨 분비의샤페로닌 10 조절
US8036710B2 (en) * 2004-05-07 2011-10-11 Qualcomm, Incorporated Power-efficient multi-antenna wireless device
BRPI0613515A2 (pt) * 2005-07-11 2011-01-11 Cbio Ltd imunomodulação induzida por chaperonina 10
AU2006269824B2 (en) * 2005-07-11 2012-04-19 Cbio Limited Chaperonin 10-induced immunomodulation
EP2463307A1 (en) 2005-08-31 2012-06-13 CBIO Limited Modified chaperonin 10
JP2009511610A (ja) * 2005-10-20 2009-03-19 シービーアイオー リミテッド 過敏症治療
AU2006303826B2 (en) * 2005-10-20 2012-07-19 Cbio Limited Treatment of hypersensitivity
NZ571696A (en) 2006-03-02 2012-04-27 Cbio Ltd Regulation of immune responses by modulation of the function of antigen presenting cells
JP2011519548A (ja) * 2008-04-11 2011-07-14 シーバイオ リミテッド 修飾型Ｃｐｎ１０およびＰＲＲシグナル伝達
US20110243921A1 (en) * 2010-03-30 2011-10-06 Cbio Limited Prevention and treatment of cutaneous lupus erythematosus
WO2013158959A1 (en) * 2012-04-19 2013-10-24 Tarix Pharmaceuticals Ltd. Compositions and methods for treatment of graft-versus-host disease
US9688741B2 (en) 2012-10-23 2017-06-27 Elastagen Pty Ltd Elastic hydrogel
CN105246520B (zh) 2012-12-10 2017-11-21 埃拉斯塔根私人有限公司 可缩放的三维弹性构建体制造
BR112016003082A8 (pt) 2013-08-13 2020-01-28 Elastagen Pty Ltd uso da tropoelastina na produção de um medicamento para cicatrização de uma ferida ou para melhora da reepitelização de uma ferida

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU684577B2 (en) * 1993-11-30 1997-12-18 University Of Queensland, The Chaperonin 10
CA2176948C (en) * 1993-11-30 2007-05-15 Halle Morton Chaperonin 10
US5989804A (en) * 1994-07-08 1999-11-23 New England Medical Center Hospitals, Inc. E6 binding proteins
WO1997005896A1 (en) * 1995-08-09 1997-02-20 Schering Corporation Combined use of interleukin-10 and cyclosporin for immunosuppression therapy
US20020142000A1 (en) * 1999-01-15 2002-10-03 Digan Mary Ellen Anti-CD3 immunotoxins and therapeutic uses therefor
WO2001017554A1 (en) * 1999-09-10 2001-03-15 Fordham University Methods and compositions for the treatment and prevention of graft rejection using heat shock proteins
GB0028122D0 (en) * 2000-11-17 2001-01-03 St Georges Entpr Ltd Method

Also Published As

Publication number Publication date
KR20050086428A (ko) 2005-08-30
NZ540433A (en) 2008-03-28
US20060198834A1 (en) 2006-09-07
CY1110972T1 (el) 2015-06-11
EP1569679B1 (en) 2010-12-01
CA2505141A1 (en) 2004-05-21
EP2255824B1 (en) 2014-07-23
DE60335202D1 (en) 2011-01-13
EP1569679A4 (en) 2008-02-27
CA2505141C (en) 2012-07-17
EP2255824A1 (en) 2010-12-01
WO2004041300A1 (en) 2004-05-21
US8067361B2 (en) 2011-11-29
JP4716731B2 (ja) 2011-07-06
US20120082690A1 (en) 2012-04-05
KR101088740B1 (ko) 2011-12-01
EP1569679A1 (en) 2005-09-07
ATE489963T1 (de) 2010-12-15
US7618935B2 (en) 2009-11-17
CN100525832C (zh) 2009-08-12
PT1569679E (pt) 2010-12-14
SI1569679T1 (sl) 2011-01-31
JP2011088920A (ja) 2011-05-06
US20100099605A1 (en) 2010-04-22
ES2351993T3 (es) 2011-02-14
AU2002952492A0 (en) 2002-11-21
JP2006508099A (ja) 2006-03-09
EP2818179A1 (en) 2014-12-31
CN1735428A (zh) 2006-02-15

Similar Documents

Publication Publication Date Title
CY1110972T1 (el) Ανοσοκαταστολη με σαπερονινη 10
CO5700767A2 (es) Procedimiento de tratamiento de rechazo de transplantes
EP1676574A3 (en) Methods for promoting survival of transplanted tissues and cells
DE60330468D1 (de) Schweine ohne jegliche expression funktioneller alpha-1,3-galactosyltransferase
ATE463256T1 (de) Mittel zur suppression von transplantat- abstossung
EA200300738A1 (ru) Защита, восстановление и усиление эритропоэтинреактивных клеток, тканей и органов
DK1487431T3 (da) Forebyggelse og/eller behandling af cardiovaskulær sygdom og/eller dermed associeret hjertefejl
NO20052505L (no) Ny bruk av dextran-sulfat
WO2004031129A3 (en) Compounds for use in the treatment of autoimmune diseases, immuno-allergical diseases and organ or tissue transplantation rejection
WO2004091436A3 (en) Methods and compositions for treating ocular disease
WO2003102162A3 (en) Novel tolerogenic dendritic cells and therapeutic uses therefor
WO2005041877A3 (en) Method of inhibiting rejection following organ transplantation
WO2005058280A3 (en) Enoximone formulations and their use in the treatment of cardiac hypertrophy and heart failure
DE69727948D1 (de) Sordarinderivate
TR200002847T2 (tr) Biçim VI 5, 6-dikloro-2-(izopropilamino) -1-(beta-L-ribofüranosil) -1H-benzimidazol.
ATE238050T1 (de) 4-cyano-4-deformylsordarizin-derivate
ATE241979T1 (de) 4-cyano-4-deformylsordarinderivate
NO20022109D0 (no) Anvendelse av treosulfan for behandling av pasienter för benmargs- eller blodstamcelletansplantasjon
NO20016326L (no) Anvendelse av proteinet UK 114 for å hindre avstötning av organtransplantatet
HUP0103107A2 (hu) Allogénikus és xenogénikus T-sejtek ex vivo kezelése gp39 antagonistákkal
UA85060C2 (ru) Биологически активная добавка к пище
RU2004128515A (ru) Способ восстановления кожного покрова при комбинированных радиационно-ожоговых поражениях